Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Jan 2018 07:00 AM
RNS
Capital Markets Day Notification
04 Jan 2018 11:04 AM
RNS
PDMR Dealing and Issue of Equity
03 Jan 2018 07:00 AM
RNS
Presenting at the Biotech Showcase, San Francisco
18 Dec 2017 04:28 PM
RNS
Issue of Equity
04 Dec 2017 11:03 AM
RNS
Posting of Annual Report and Notice of AGM
30 Nov 2017 10:57 AM
RNS
Issue of Equity
15 Nov 2017 07:00 AM
RNS
Covance to Present Affimer Data at Conference
14 Nov 2017 03:27 PM
RNS
Holding(s) in Company
13 Nov 2017 07:00 AM
RNS
Avacta to present at PEGS Europe
13 Nov 2017 07:00 AM
RNS
Avacta to Present at Investor Evening
24 Oct 2017 07:00 AM
RNS
Affimers in Scientific Publications
19 Oct 2017 07:00 AM
RNS
Private Shareholder Update Event
16 Oct 2017 10:42 AM
RNS
Hardman Res.: R&D accelerated to advance assets
12 Oct 2017 07:00 AM
RNS
Avacta to Present at Shares Spotlight Evening
10 Oct 2017 07:00 AM
RNS
Avacta to Present at Major US Conference
09 Oct 2017 04:02 PM
RNS
Director Dealing and Issue of Equity
05 Oct 2017 07:00 AM
RNS
Research collaboration with FIT Biotech Oy
04 Oct 2017 07:00 AM
RNS
Preliminary Results
02 Oct 2017 07:00 AM
RNS
Avacta establishes US business development team
07 Sep 2017 07:00 AM
RNS
Notice of Results
21 Aug 2017 12:00 PM
RNS
Director/PDMR Shareholding
07 Aug 2017 07:00 AM
RNS
Trading Update
31 Jul 2017 12:00 PM
RNS
Issue of Equity
28 Jul 2017 01:15 PM
RNS
Director/PDMR Shareholding
05 Jul 2017 07:00 AM
RNS
Director Dealing and Issue of Equity
04 Jul 2017 07:00 AM
RNS
Manchester ShareSoc Growth Company Seminar
05 Jun 2017 07:00 AM
RNS
ShareSoc Growth Company Seminar
01 Jun 2017 08:56 AM
RNS
Issue of Equity
22 May 2017 07:00 AM
RNS
2 Biotech's Licence Affimers for Research Use
10 May 2017 07:00 AM
RNS
Key Affimer Patent To Be Granted in China
08 May 2017 01:21 PM
RNS
Hardman Research: De-risking Moderna's partnership
05 May 2017 07:00 AM
RNS
Presenting at the Hardman Private Investor Forum
02 May 2017 07:00 AM
RNS
Avacta to Present at BioTrinity 2017
24 Apr 2017 07:00 AM
RNS
Diagnostics firm take rights to several Affimers
19 Apr 2017 07:00 AM
RNS
Avacta to Present at the Shares Spotlight Evening
12 Apr 2017 07:15 AM
RNS
Hardman Research: Another important box ticked
06 Apr 2017 02:23 PM
RNS
Holding(s) in Company
06 Apr 2017 02:23 PM
RNS
Holding(s) in Company
06 Apr 2017 10:22 AM
RNS
Director/PDMR Shareholding
03 Apr 2017 07:00 AM
RNS
Results of Immunogenicity Study with Human Samples
03 Apr 2017 07:00 AM
RNS
Interim Results for the Period Ended 31 Jan 2017
31 Mar 2017 09:31 AM
RNS
Avacta Presents at Investor Evening Hosted by TPI
31 Mar 2017 07:00 AM
RNS
London Growth and Innovation Forum Presentation
22 Mar 2017 09:00 AM
RNS
Avacta to present at the UK Investor Show
21 Mar 2017 07:15 AM
RNS
Hardman Research: Low response would be positive!
30 Jan 2017 07:00 AM
RNS
Director/PDMR Shareholding
20 Jan 2017 11:35 AM
RNS
Result of Annual General Meeting
20 Jan 2017 07:00 AM
RNS
Trading Update
11 Jan 2017 07:00 AM
RNS
Presenting at London Growth and Innovation Forum
05 Jan 2017 07:00 AM
RNS
Director Dealing and Issue of Equity

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100

Latest directors dealings